V

VYNE Therapeutics

D
VYNE
USD
-0.157
(-4.7619%)
Market Closed
4,923.00
Volume
-0.81
EPS
-
Div Yield
1.82558
P/E
46,313,106.58
Market Cap
Today
0.1595%
1 Week
15.441%
1 Month
71.585%
6 Months
7.904%
12 Months
-10.795%
Year To Date
33.051%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
D
DERM
0.24
(4.3956%)
USD
E
EOLS
-2.495
(-14.8733%)
USD
M
MNK
-0.0649
(-16.0683%)
USD
A
ALKS
-0.25
(-0.8556%)
USD
A
ALIM
(%)
USD
A
ANIK
0.02
(0.1161%)
USD
A
ARGX
2.01
(0.3414%)
USD
B
BHC
-0.075
(-0.7891%)
USD

Title:
VYNE Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Do you need help or have a question?
Contact Us